Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 12-Month High – Should You Buy?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s share price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $15.48 and last traded at $15.57, with a volume of 440107 shares changing hands. The stock had previously closed at $14.69.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Truist Financial raised their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. UBS Group assumed coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective for the company. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Finally, Barclays upped their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.80.

Amneal Pharmaceuticals Stock Performance

The company has a 50-day simple moving average of $12.82 and a 200-day simple moving average of $13.02. The company has a market cap of $4.87 billion, a price-to-earnings ratio of 40.24 and a beta of 1.30.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The business had revenue of $722.52 million during the quarter. As a group, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director directly owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This represents a 27.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kemnay Advisory Services Inc. purchased a new position in Amneal Pharmaceuticals in the 4th quarter valued at approximately $26,000. Federated Hermes Inc. boosted its position in Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares in the last quarter. Comerica Bank grew its holdings in Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares during the last quarter. Spire Wealth Management increased its position in shares of Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after buying an additional 1,023 shares in the last quarter. Finally, Transamerica Financial Advisors LLC raised its stake in shares of Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after buying an additional 2,460 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.